AXIM Signs CRO Deal with Ophthalmology Trials --

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
517
AXIM Signs CRO Deal with Ophthalmology Trials -- SECFilings.com

REDONDO BEACH, CA--(Marketwired - Mar 22, 2017) - SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.'s ( OTCQB : AXIM ) recent engagement of a contract research organization -- or CRO -- to advance the development of its ophthalmology franchise.

The global market for glaucoma and dry eye treatments could surpass $10 billion over the coming years. Since the 1970s, researchers have noticed that cannabinoids could play a vital role in treating these conditions. The application of cannabinoids to the treatment of these conditions could unlock significant long-term potential for both patients and companies bringing these innovative new drugs to market.

AXIM Biotech hopes to harness the power of cannabinoids to treat glaucoma and dry eye through its AX-1603 and AX-1606 clinical programs. Recently, the company retained Ora Inc., a global contract research organization ("CRO"), to perform the company's upcoming product development and clinical trials in these areas. As a leading ophthalmology CRO, Ora has extensive experiencing advancing products from preclinical to post-marketing phases.

The clinical trials will be run under the supervision of Prof. Robert Ritch, Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York. Prof. Ritch is a world-renowned expert in ophthalmology and glaucoma in particular and has joined the company's Board of Advisors in December 2016 -- a significant win for the company's ophthalmology program.

Please follow the link to read the full article:

http://analysis.secfilings.com/articles/156-a...y-treatm...

About SECFilings.com

Founded in 2004, SECFilings.com provides free real-time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx .

Contact: Paul Archie 406 862 2242 parchie@tdmfinancial.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading

Top 5 Most Recently Viewed Articles

SBVA Triumphs as Venture Capital Leader in Prestigious Award

Updated Category News Views 194

SBVA Achieves Prestigious Recognition SBVA, formerly known as SoftBank Ventures Asia, recently earned the esteemed title of "VC of the Year" at the annual Korea Venture Capital Awards. This significant honor highlights SBVA's remarkable investment performances and its vital role in enhancing the venture ecosystem. The Importance of the Korea Venture Capital Awards The...

Continue Reading
Strategic Acquisition: TopBuild Expands with Metro Supply Company

Updated Category News Views 116

Strategic Acquisition by TopBuild TopBuild Corp. (NYSE:BLD), a leader in insulation installation and specialty distribution for the construction sector, has recently made a significant move by agreeing to acquire Metro Supply Company. This acquisition is set to enhance TopBuild’s offerings in the commercial and industrial insulation market and is expected to bring in...

Continue Reading
Key Class Action Update on MoonLake Immunotherapeutics (MLTX)

Updated Category News Views 117

MoonLake Immunotherapeutics Faces Class Action Lawsuit Investors should be aware that MoonLake Immunotherapeutics (NASDAQ: MLTX) is currently facing a class action lawsuit due to alleged violations of securities laws. The DJS Law Group is actively reminding shareholders of their rights in light of this legal action, emphasizing the importance of staying informed during...

Continue Reading
Columbus McKinnon Set to Shine at Global Industrial Conference

Updated Category News Views 119

Columbus McKinnon Corporation's Participation in a Key Event Columbus McKinnon Corporation (Nasdaq: CMCO), a prominent name in the design and manufacturing of motion solutions, is excited to announce its participation in an upcoming event that is significant for the industry. The company will showcase its expertise at the Baird Global Industrial Conference. This important...

Continue Reading
The Growth of a $100 Investment in Norfolk Southern Over 20 Years

Updated Category News Views 64

The Benefits of Long-Term Investments in Norfolk Southern Investing wisely can truly change your financial landscape, and Norfolk Southern (NYSE: NSC) is a stellar example of this. Over the last 20 years, investing in NSC has yielded remarkable results, achieving an annualized growth rate of 5.31%. This outstanding performance has led to an impressive average annual...

Continue Reading